Subcutaneous Daratumumab Combination Resulted in Deep and Rapid Hematologic Responses and Improved Clinical Outcomes in the Treatment of Patients with Newly Diagnosed Light Chain (AL) Amyloidosis
- Saturday, June 13, 2020, 7:23
- PR Newswire
- Add a comment
RARITAN, N.J., June 13, 2020 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the first randomized Phase 3 study investigating subcutaneous daratumumabi in the treatment of patients with newly diagnosed light chain (AL) amyloidosis, a…
About the Author
admin has written 21043 stories on this site.